Discovery of deaminase functions by structure-based protein clustering

share:

Brief intro:

  • Author: Jiaying Huang, Qiupeng Lin, Hongyuan Fei, Zixin He, Hu Xu, Yunjia Li, Kunli Qu, Peng Han, Qiang Gao, Boshu Li, Guanwen Liu, Lixiao Zhang, Jiacheng Hu, Rui Zhang, Erwei Zuo, Yonglun Luo, Yidong Ran, Jin-Long Qiu, Kevin Tianmeng Zhao, Caixia Gao
  • Journal: Cell
  • Doi: https://www.doi.org/10.1016/j.cell.2023.05.041
  • Publication Date: 2023 Jun 27

Products/Services used in the paper

Request Quote

Abstract

The elucidation of protein function and its exploitation in bioengineering have greatly advanced the life sciences. Protein mining efforts generally rely on amino acid sequences rather than protein structures. We describe here the use of AlphaFold2 to predict and subsequently cluster an entire protein family based on predicted structure similarities. We selected deaminase proteins to analyze and identified many previously unknown properties. We were surprised to find that most proteins in the DddA-like clade were not double-stranded DNA deaminases. We engineered the smallest single-strand-specific cytidine deaminase, enabling efficient cytosine base editor (CBE) to be packaged into a single adeno-associated virus (AAV). Importantly, we profiled a deaminase from this clade that edits robustly in soybean plants, which previously was inaccessible to CBEs. These discovered deaminases, based on AI-assisted structural predictions, greatly expand the utility of base editors for therapeutic and agricultural applications.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download